关注并星标CPHI制药在线大概一个月前,翰森制药宣布与再生元(Regeneron)达成合作协议,将授予后者开发、生产及商业化HS-20094的全球独占许可(不含中国内地、中国香港及中国澳门)权利。HS-20094是翰森制药在研的一款GLP-1/GIP双受体激动剂,已成功完成多项II期临床试验,具有积极的疗效和安全性数据。此次合作,翰森制药将获得8000万美元首付款,以及最高19.3亿美元里程碑付款...
Source Link关注并星标CPHI制药在线大概一个月前,翰森制药宣布与再生元(Regeneron)达成合作协议,将授予后者开发、生产及商业化HS-20094的全球独占许可(不含中国内地、中国香港及中国澳门)权利。HS-20094是翰森制药在研的一款GLP-1/GIP双受体激动剂,已成功完成多项II期临床试验,具有积极的疗效和安全性数据。此次合作,翰森制药将获得8000万美元首付款,以及最高19.3亿美元里程碑付款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.